Do you want to read an article? Please log in or register.
EUROHELICAN-The First Helicobacter Pylori Screen-and-Treat Population-Based Study in Young Adults in Europe
Gastrointestinal CancerHelicobacter Pylori
Related content
Helicobacter Pylori
Susceptibility-Guided Versus Empirical First-Line Therapy of Helicobacter pylori Infection in Adults: A Systematic Review and Meta-Analysis
Helicobacter
Rocha MC, Gaspar T, Bernardes C, Nunes PP
doi: 10.1111/hel.70125
Helicobacter Pylori
Bismuth-Amoxicillin-Vonoprazan Triple, Amoxicillin-Vonoprazan Dual, and Clarithromycin-Based Triple Therapies for First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Open-Label, Randomized Trial
Helicobacter
Hsu PI, Sheu MJ, Chen CL, Lei WY, Shih CA, Tsay FW, Kao SS, Shie CB, Wu PJ, Kuo CH, Yang JC, Chen KY, Chuah SK, Lee CL, Lee HC, Tai WC, Tsai TJ, Kao JY, Wu DC, Taiwan Acid‐related Disease & Microbiota (TARD‐M) Consortium
doi: 10.1111/hel.70131
Helicobacter Pylori
Efficacy and Safety of Tegoprazan-Based Dual, Triple, and Quadruple Therapies in First-Line Helicobacter pylori Eradication: A Prospective Randomized Controlled Trial
Helicobacter
Zhu YC, Li K, Sun A, Lin S, Zhang J, Meng S, Xia X, Gao H, Lin J, Jiang W
doi: 10.1111/hel.70147
Helicobacter Pylori
EUROHELICAN-Accelerating Gastric Cancer Reduction Through Helicobacter pylori Eradication
Helicobacter
Tepeš B, Bric TK, Oblak M, Završnik J, Vošner HB, Ražuka-Ebela D, Leja M, Knaze V, Park JY, Matysiak-Budnik T
doi: 10.1111/hel.70097
Helicobacter Pylori
High Eradication Rate of a Potassium-Competitive Acid Blocker-Based Minocycline, Furazolidone, and Bismuth Regimen for Refractory Helicobacter pylori Infection: A Real-World Study
Helicobacter
Li JY, Han YY, Li DY, Liu JM, Zhou ZZ, Zhou YN, Tuo L, Yao XJ, Liu M, Wang G, Li PY
doi: 10.1111/hel.70128
RECOMMENDED
Gastrointestinal Cancer
Rising early-onset colorectal cancer in Switzerland despite declining incidence in older adults: A nationwide population-based study, 1980-2021
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Eur J Cancer
Fournier E, Schaffar R, Staehelin K, Rouxel N, Ris F, Toso C, Frossard JL, Rapiti E, Koessler T, Wildisen L, Meyer J
doi: 10.1016/j.ejca.2026.116707
Helicobacter Pylori
Long-Term Effect of Macrolides on Helicobacter pylori Eradication: Data From the European Registry on Helicobacter pylori Management (Hp-EuReg)
Helicobacter
Nyssen OP, Ortega GJ, Jonaitis L, Pérez-Aísa Á, Tepes B, Lucendo AJ, Tejedor-Tejada J, Bumane R, Garre A, Huguet JM, Perona M, Núñez Ó, Pabón-Carrasco M, Castro-Fernández M, Areia M, Barrio J, Loro AM, Butler TJ, Marcos MS, Keco-Huerga A, Cajal MD, Denkovski M, Pavoni M, Buzás GM, Lerang F, Losurdo G, Wolfe García PM, Phull PS, Martínez-Domínguez SJ, Kupcinskas J, Leja M, Marcos-Pinto R, Smith SM, Gasbarrini A, Papp V, Rodríguez BJG, Alonso MS, Villarroya RP, Mejide PP, Jiménez-Moreno M, Pascual-Mato M, Bravo-Pache C, Montes M, Cano-Català A, Parra P, Moreira L, Mégraud F, O'Morain C, Bujanda L, Gisbert JP, Hp‐EuReg investigators
doi: 10.1111/hel.70107
Helicobacter Pylori
Tegoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial
Helicobacter
Park JY, Hong SJ, Choi IJ, Baik GH, Kim SM, Park JJ, Jeon SW, Kim KO, Lee SK, Jung HY, Oh JH, Park CH, Kim SW, Shim KN, Jee SR, Moon HS, Moon JS, Choi CW, Lee WS, Kim JG
doi: 10.1111/hel.70106
Helicobacter Pylori
Efficacy and Safety of Levofloxacin- Versus Moxifloxacin-Based Nitazoxanide Quadruple Therapy as Second-Line Treatment for Helicobacter pylori in Egypt: A Randomized Multicenter Trial
Helicobacter
El-Azab G, Abdel Salam S, Moustafa E, Abuoelhassan A, Shamseya A, Ellakany A, Abdelaal U, Assem M, Khalil F, Mahmoud A, Elsabaawy M, Hussein B, Ezz-Eldin M, Hassany S, Zaghloul N, Magdy M
doi: 10.1111/hel.70104